Traws Pharma, Inc. (TRAW)

On May 8, 2026, Traws Pharma's stock price jumped 30% in early trade following the announcement of plans to advance potential clinical candidates for the treatment of hantavirus infections. This intraday jump extended a strong run for TRAW shares, which had already climbed about 19% in May through the previous day's close.

The provided search results do not contain specific information about demand seasonality for Traws Pharma, Inc.'s products and services. However, demand for its antiviral treatments could exhibit some seasonality, potentially increasing during typical flu seasons or periods of heightened viral outbreaks.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases and cancer. The company integrates antiviral drug development, medical intelligence, and regulatory strategy to address challenges in treating viral infections. Its work centers on investigational oral small-molecule antiviral agents with activity against virus strains such as COVID-19/Long COVID, bird flu (H5N1), and seasonal influenza. The company's major product candidates include Tivoxavir marboxil (TXM) for bird flu and seasonal influenza, Ratutrelvir (TRX01) for COVID-19, Narazaciclib (ON 123300) for breast and endometrial cancers, and Rigosertib for recessive dystrophic epidermolysis bullosa-associated locally advanced or metastatic squamous cell carcinoma (RDEB SCC). Traws Pharma also plans to advance potential clinical candidates for hantavirus infections.

Traws Pharma, Inc. is headquartered in Newtown, Pennsylvania, United States.

The provided search results do not contain specific information regarding Traws Pharma, Inc.'s brand reputation or any events that have affected it in the past year.

The provided search results do not contain specific details about major institutional and individual owners of Traws Pharma, Inc.